Spirogen Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (30)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Spirogen - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Spirogen. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “8” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Spirogen - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Spirogen - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Spirogen. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “8” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Spirogen - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Spirogen

  1.1 Business Overview

  1.2 Spirogen Cancer Pipeline Overview

 

2. Spirogen Cancer Drugs in Preclinical Phase

  2.1 Antibody Drug Conjugates - ADC Therapeutics

  2.2 Anticancer Therapies - Spirogen

  2.3 Centanamycin

 

3. Spirogen Cancer Drugs in Phase-I

  3.1 SGN CD123A

  3.2 SGN CD19B

  3.3 SGN CD70A

 

4. Spirogen Cancer Drugs in Phase-I/II

  4.1 SG 2000

 

5. Spirogen Cancer Drugs in Phase-III

  5.1 Vadastuximab Talirine

 

6. No Development Reported in Cancer Drugs in Clinical Pipeline

  6.1 Antibody Drug Conjugates - Spirogen

  6.2 c-Met Inhibitors - Spirogen

  6.3 DNA Minor Groove Binding Agents - Spirogen

  6.4 Antibody-Drug Conjugates - PolyTherics/Spirogen

  6.5 Anticancer Conjugated Nanobodies - Ablynx/Spirogen

  6.6 Antibody Drug Conjugates - Genentech/Spirogen

  6.7 Targeted Cancer Therapies - Spirogen


Figure 1-1: Spirogen Cancer Pipeline by Phase (%)

Figure 1-2: Spirogen Cancer Pipeline by Phase (Number)